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Abstract: Every day, new information is presented with respect to how to best combat the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This manuscript sheds light on such
recent findings, including new co-factors (i.e., neuropilin-1) and routes (i.e., olfactory transmucosal)
allowing cell entry of SARS-CoV-2 and induction of neurological symptoms, as well as the new SARS-
CoV-2 variants. We highlight the SARS-CoV-2 human–animal interfaces and elaborate containment
strategies using the same vaccination (i.e., nanoparticle “NP” formulations of the BNT162b2 and
mRNA-1273 vaccines) for humans, minks, raccoon dogs, cats, and zoo animals. We investigate the
toxicity issues of anti-CoV NPs (i.e., plasmonic NPs and quantum dots) on different levels. Namely,
nano–bio interfaces (i.e., protein corona), in vitro (i.e., lung cells) and in vivo (i.e., zebrafish embryos)
assessments, and impacts on humans are discussed in a narrative supported by original figures.
Ultimately, we express our skeptical opinion on the comprehensive administration of such antiviral
nanotheranostics, even when integrated into facemasks, because of their reported toxicities and the
different NP parameters (e.g., size, shape, surface charge, and purity and chemical composition of
NPs) that govern their end toxicity. We believe that more toxicity studies should be performed and
be presented, clarifying the odds of the safe administration of nanotoxocological solutions and the
relief of a worried public.
Keywords: SARS-CoV-2; human–animal interfaces; nanoparticles; nanotoxicology; lung cell lines;
zebrafish; skeptical opinion
1. Introduction
1.1. SARS-CoV-2: Recent Discoveries
Coronaviruses (CoVs; falling under the order Nidovirales, family Coronaviridae, and
subfamily Coronavirinae) are versatile enveloped single-stranded RNA viruses, causing
respiratory, enteric, hepatic, and neurological diseases of a broad severity spectrum among
different animals and humans [1]. Patients afflicted with the severe form of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-1, and the Middle East
respiratory syndrome coronavirus (MERS-CoV) share the key feature of developing acute
respiratory distress syndrome (ARDS). A holistic feature associated with SARS-CoV-2
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infected patients is the cytokine storm (i.e., excessive production of proinflammatory cy-
tokines enhanced by the activated coagulation cascade), characterized by long-lived lung
damage and fibrosis that may cause the low quality of life, multiorgan failure, and ulti-
mately death [2,3]. One appealing work that shed light on a new multisystem inflammatory
syndrome (MIS-C) that expressed cytokine storm (i.e., high serum IL-6 levels with a need
for positive inotropic support), and was detected in SARS-CoV-2 infected older school-aged
children and adolescents. The work compared the clinical features of MIS-C with Kawasaki
disease (KD, a febrile children’s illness, including inflammation of the blood vessels that
could cause dilatation of coronary arteries). The main differences were as follows: (i) the
epidemiology of MIS-C was correlated with African descent children, and no cases were
detected in China and Japan. On the contrary, Asian children demonstrated the highest
KD in the world; and (ii) there was an age bias for MIS-C, with it being reported mainly
in older children and adolescents. Conversely, KD occurred in children <5 years old and
peaked at ~10 months old. The reasons behind the epidemiology of MIS-C, especially its
absence in China (i.e., the country firstly reported SARS-CoV-2) and the contributing link
of SARS-CoV-2 to the coronary dilatation in children, still need to be elucidated [4].
One team of researchers [5] unraveled the contribution of the stability of SARS-CoV-2
in aerosols and on surfaces to the induced super-spreading events, shedding light on
the credibility of SARS-CoV-2 aerosol and fomite transmission. SARS-CoV-2 remained
viable and infectious in aerosols for three hours and for up to three days on surfaces, with
greater stability on plastic and stainless steel than on copper and cardboard. Every day,
a new scientific clue is being discovered on the SARS-CoV-2. Excitingly, one group of re-
searchers [6] recently shifted the attention from the role of angiotensin-converting enzyme
2 (ACE2) as the primary mediator behind the uptake of SARS-CoV-2 to the substantial role
of other co-factors, facilitating SARS-CoV-2 cell entry independently of ACE2. Namely,
neuropilin-1 (NRP1, binding furin-cleaved substrates) facilitated SARS-CoV-2 infectivity.
The authors also demonstrated the blockage of this NRP1 role by a monoclonal blocking
antibody against NRP1, using 80 nm Ag NPs coated with prototypic NRP1-binding CendR
peptide RPARPAROH. They concluded that NRP1 could be a potential target for novel
antiviral drugs inhibiting SARS-CoV-2 infections. Another investigation [7] demonstrated
transmucosal SARS-CoV-2 entry via regional nervous structures with olfactory tract trans-
portation, explaining the reasons behind the associated neurological loss of smell and taste
of COVID-19 patients. The study was executed on 33 fatal COVI-19 cases while investi-
gating the olfactory mucosa, its nervous projections, and other central nervous system
(CNS) regions. Viral RNA loads were detected by RT-qPCR. Interestingly, the highest
SARS-CoV-2 RNA levels of SARS-CoV-2 S protein were detected in the olfactory mucosa
and micro-thrombosis, and CNS infarctions were identified in 18% of cases. Another
work [8] demonstrated that the SARS-CoV-2 spike protein mutation (D614G substitution)
enhanced viral replication (via the increased infectivity and stability of G614 virions) in
human lung epithelial cells and primary human airway tissues. Infected Syrian hamsters
showed higher G614 viral titers in the upper airways (i.e., nasal washes and trachea) than
in the lungs, suggesting a critical role played by D614G substitution in the enhanced viral
replication in the upper respiratory tract that might propose higher viral transmissibility.
Furthermore, the sera of infected hamsters demonstrated higher antibody neutralization
titers against the G614 virus than the D614 virus, drawing an observation that the D614G
substitution might decrease the potency of the COVID-19 vaccine candidates based on
the original D614 sequence. The authors recommended further studies on the emerging
SARS-CoV-2 mutations and their impact on the efficacy of vaccine candidates.
The SARS-CoV-2 viral genome is composed of 29,903 nucleotides [9]. A research
team [10] demonstrated the evolution of a drastically reduced CG content in open read-
ing frames (ORFs) of SARS-CoV-2 with a frequency of only 1.47% (i.e., 439 CGs/29,902
nucleotides), which is much less than the expected 3.60% CG dinucleotide frequency in
the viral genome. Based on the energy usage bases, a coronavirus with low CG content
translates its RNA more efficiently. This efficiency stems from the lower energy required
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to disrupt stem-loops formed in the viral genome’s secondary structure, meaning less
stable ORFs that do not adversely recruit host ribosomes to start viral RNA translation.
Consequently, the team claimed that SARS-CoV-2 was less virulent than the MERS-CoV in
the highly stable ORFs.
1.2. SARS-CoV-2: Human–Animal Interfaces
One cause of concern and speculation since the beginning of the pandemic has been
virus transmission between animals and humans. Supposedly, this transmission could lead
to virus reservoirs among companion animals and wildlife and new vaccine-resistant mu-
tations, which would greatly hinder the efforts to control the pandemic. Since spring 2020,
SARS-CoV-2 outbreaks have been reported in mink farms in several countries, including
signs of both human-to-mink and mink-to-human transmission [11]. These transmission
signs triggered the European Centre for Disease Prevention and Control [12] and the WHO
to highlight the importance of surveying the human–animal interface and collaboration
among virologists and epidemiologists to tackle viral mutations. Specifically, farms, where
animals live in crowded conditions, could be ideal for efficient, rapid viral spread and muta-
tion formation. The viral RNA has been detected in airborne inhalable dust of mink farms,
leading to speculation that dust may be a means of transmission among minks, as well as
raising concerns about human occupational exposure. Despite the best efforts to prevent
SARS-CoV-2 spread, the virus has spread widely on mink farms in the Netherlands (i.e., in
North Brabant Noord Brabant, and Limburg provinces) [13] and Denmark, with detections
also reported in Spain, France, Italy, Sweden, Greece, Canada, and Lithuania (reported as
of the 4th of January 2021 by the OIE-World Organization for Animal Health [14]). The
number of culled mink in the Netherlands during the outbreak has exceeded 2.7 million
animals, which is much more (6.5 times) than the number of confirmed human cases [15].
SARS-CoV-2 has also been reported in mink from Poland (i.e., the second-largest pro-
ducer of mink pelts in Europe, following Denmark, with 15 positive cases at a farm in
Northern Poland) [16]. The USA is also a leading mink producer, and considering the
surge of reported SARS-CoV-2 infected human individuals in these countries (i.e., the
USA, Denmark, Poland, the Netherlands, and Canada) linked with specific high mink
densities, it is strongly speculated that there are possible unreported SARS-CoV-2 infections
in commercial fur farms [17].
When three farms in Northern Jutland in Denmark reported SARS-CoV-2 infected
mink individuals, all SARS-CoV-2 RNA mink sequences showed a mutation (nt C25936T
[as cDNA] encoding H182 to Y within ORF3a) that was also found in the associated
human individuals. Despite the absence of this mutation in human SARS-CoV-2 Jutland
sequences before 10 June 2020, it hit more than 40% frequency between 10 June and 1 July
2020. Moreover, this mutation was found in a NB03 mink farm in the Netherlands [18].
Another mutation was detected in the spike gene (A22920T, encoding Y453 to F) in these
three Danish farms and a farm in the Netherlands. In the same vein, this mutation was
not present in humans before June 10, but later on, was detected in humans linked to
infected farms in Denmark. One more mutation in the ORF1b gene (C15656T, encoding
T730 to I) was only detected in mink-human sequences from Denmark and a sequence
from New Zealand [18]. The Danish health authorities then announced a saddening mink
culling (i.e., 17 million animals) following the rapid uncontrolled spread of SARS-CoV-2 in
mink farms (i.e., more than 200 farms since June), mink-associated mutations, and human
cases infected with mink-related variants in regions of such mink farms. What raised
alarm bells were the following: (i) the viral mutations (i.e., Cluster-5 variant causing two
deletions in the spike protein) in samples collected from mink and infected people; and
(ii) the suggested decreased ability of antibodies of recovered human cases to neutralize
the Cluster-5 variants, triggering the concern that the variant could make the vaccines less
effective, even though this Cluster-5 variant almost stopped spreading and had not been
detected since September [19].
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Regarding SARS-CoV-2 infections in other animals, a new work [20] identified the
susceptibility of raccoon dogs to SARS-CoV-2 infection and the ability of raccoons to
transmit the virus to directly to animals they come in contact with. A recent review [21]
investigated the critical role of animals as reservoirs, natural hosts, and experimental
models for SARS-CoV-2. Regarding reservoir animals, there is some consensus on the
evolution of SARS-CoV-2 following multiple “mosaic” recombination events of the bat and
pangolin SARS-related CoVs (SARSr-CoVs) due to the 96% genetic similarity of SARS-CoV-
2 and horseshoe bat SARSr-CoV (designated RaTG13). Concerning natural infections of
animals, the review reported the following: (i) dogs (in Hong Kong and Germany) were
identified positive for SARS-CoV-2 with speculation of human-to-dog transmission from
the infected owners; (ii) cats in China, Hong Kong, USA, Belgium, have been found to
be positive for SARS-CoV-2, suggesting human-to-cat transmission, with cats having a
greater susceptibility to SARS-CoV-2 than dogs; and (iii) tigers and lions in zoos (in the
USA) were confirmed to be positive for SARS-CoV-2, with infection assumed to be from
an asymptomatic infected zookeeper. Experimental animal models, monkeys, hamsters,
ferrets, cats, tree shrews, transgenic mice, and fruit bats are regarded as appropriate animal
models for studying the transmission and pathogenesis of viral infection and replication.
Moreover, monkeys (i.e., rhesus macaques are considered to be a suitable animal model
for investigating vaccine efficacy against SARS-CoV-2, in a similar fashion to their use in
SARS-CoV and MERS-CoV [21].
1.3. Repurposed Drugs and Vaccines against SARS-CoV-2
A futile question that will require a couple of years before it can be answered is “what
is the specific antiviral drug that could combat the COVID-19?” Instead, we could ask more
realistic questions, such as “what are the potential repurposed drugs that could solve the
current pandemic node?” A recent work [2] mentioned a couple of host-directed therapies,
including metformin, glitazones, fibrates, sartans, and atorvastin to boost the immune
response preventing ARD and zinc formulations possessing some antiviral properties,
as adjuvants with antiviral therapies targeting COVID-19. Moreover, cellular therapy
using allogeneic mesenchymal stromal cells reduced non-productive inflammation and
laid the ground for a new therapy path under clinical trials (phase I/II) for ARD patients.
Additionally, prophylactic doses of low-molecular-weight heparin are the mainstay in pre-
venting venous thromboembolism in hospitalized COVID-19 patients. Drugs antagonizing
thrombin (i.e., a protease serve clot formation) receptors could also play a promising role
in mitigating the severity and bad prognosis of COVID-19 [3]. Based on the preliminary
results of a RECOVERY trial, a low dose (6 mg once daily for ten days) of dexamethasone,
dubbed ‘a major breakthrough’, reduced deaths by one-third in hospitalized COVID-19
patients under ventilation (2104 patients) and by one-fifth in hospitalized patients under
standard healthcare (4321 patients) [22]. Dexamethasone is a glucocorticoid with anti-
inflammatory effects mimicking those of the natural hormones (i.e., cortisol in humans and
corticosterone in rodents), inhibiting the release of inflammatory chemokines and reducing
lung inflammation and ARDS severity [23,24]. Attention has been directed towards the
use of psychotropic drugs (e.g., nicotine, the anti-psychotic aripiprazole, and the anti-
depressant sertraline) preventing SARS-CoV-2 infections after noticing the conflicting fact
of almost empty COVID-19 units in the psychiatric clinics in France. This conflict stemmed
from the thought that psychiatric clinics would be a focal point for disseminating the infec-
tion due to the non-adherence of psychiatric patients to protective measures and their late
seeking of medical help, as they experience social discrimination. These psychotropic drugs
are cationic amphiphilic drugs (CADs), disturbing intracellular trafficking. Even though
nicotine is a partial CAD, it could specifically bind to specific receptors (e.g., acetylcholine,
angiotensin-converting enzyme 2, and sigma-1), preventing SARS-CoV-2 cellular entry
and inducing different molecular consequences [25]. A group of researchers [26] showed
an antiviral effect of the other repurposed anti-parasitic ivermectin against SARS-CoV-2
in vitro (i.e., in the infected Vero/hSLAM cells), reducing the viral replication by ~5000 fold
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in SARS-CoV-2 RNA analyzed by RT-PCR within 24 to 48 h. The researchers speculated
the possible mechanism behind this antiviral action to be the binding of ivermectin to the
importin α/β1 heterodimer, preventing its binding to the coronavirus protein and conse-
quently preventing the viral protein entry to the nucleus. This ivermectin viral inhibition
could be correlated with previous inhibitions demonstrated against other RNA viruses (i.e.,
non-structural protein 5 inhibition of dengue virus serotypes 1 and 2 by the ivermectin
blockage to nuclear transporter importin α/β, in vitro) [27].
The world was breathing a sigh of relief with the emergence of some vaccine candi-
dates against SARS-CoV-2 when the worrying news came from England (on December
13, 2020, from south-eastern England, Wales, and Scotland) about a new variant of SARS-
CoV-2 coined VUI-202012/01 (i.e., the first “Variant Under Investigation” in December
2020). This VUI-202012/01 (20B/501Y.V1) variant has undergone 17 mutations. N501Y
(i.e., a mutation in the spike protein) was defined as one of the most critical mutations,
rendering the virus more infectious and more highly spreading. However, confirmation
that the variant was the causative agent of the rise in such cases could not be drawn yet.
On December 21, 2020, the Public Health England [28] released the exact number of 23 mu-
tations, namely 13 non-synonymous mutations (i.e., a series of spike protein mutations
and a stop codon mutation in ORF8), four amino acid deletions, and six synonymous
mutations (i.e., with five in ORF1ab as C913T, C5986T, C14676T, C15279T, and C16176T,
and one in the membrane gene as T26801C). Still, a recent study [29] updated the number
of mutations to 24, including 14 non-synonymous mutations with the N501Y mutation
in the receptor-binding domain (RBD) of the spike protein, still being recognized as an
alarming mutation. The study estimated that this 501Y lineage with ∆69/∆70 amino acid
deletion that began spreading in the UK from late September and which predominated
in December 2020 (i.e., 501Y Variant 2) was 75% (i.e., 70 to 80%) more transmissible than
the 501N lineage [29]. Meanwhile, the earlier 501Y lineage without amino acid deletion
∆69/∆70 (i.e., 501Y Variant 1) that circulated mainly in the UK from early September to
mid-November was only 10% (i.e., 6 to 13%) more transmissible than the 501N lineage.
Similarly, another 501Y lineage (i.e., 20C/501Y.V2 with ∆69/∆70 amino acid deletion) with
critical mutations in the RBD, namely, K417N, E484K, and N501Y, detected in South Africa,
spread from October to November 2020 in Eastern Cape Province [30], and remained
genetically distant from the UK 501Y Variant 2 [29]. This South African variant spread
widely, circulating in both Eastern and Western Cape Provinces [30], with its two mutations
(i.e., E484K and N501Y) in the receptor-binding motif that mainly forms the interface with
the human ACE2 receptor. On the one hand, SARS-CoV-2 is an RNA virus that mutates
naturally during replication, and the leading vaccine candidates target the spike protein,
which has already undergone mutations. On the other hand, vaccines provoke antibody
production against several regions in the spike protein. Therefore, the chance of a single
change of spike protein causing a vaccine’s ineffectiveness remains low [31].
1.4. Nanotheranostics: Swaying from Anti-Coronavirus to Toxicological Properties
The term “theranostics” refers to the combination of diagnostic and therapeutic prop-
erties within a single agent. Using the advantages of nanotechnology to refine the term
into nanotheranostics as an “all-in-one approach” facilitates precision medicine [32,33]. An
intriguing property of NPs is that they share the nanometer size distribution with viruses.
Consequently, NPs can enter virus-targeted cells in a similar way to viruses [34]. Nan-
otechnology could be appealing in vaccine design, since NPs could be ideally utilized as
carriers for antigen delivery, adjuvants, and mimicking agents for viral structures [35]. On
18 November 2020, the promising news of SARS-CoV-2 prophylaxis came from the BioN-
tech and Pfizer companies, declaring the results of their COVID-19 vaccine (i.e., BNT162b2)
phase 3 clinical trial. This news came directly after Moderna announced the preliminary
outcomes of their phase 3 study for the other vaccine (i.e., mRNA-1273), developed by the
Cambridge-based biotech company in collaboration with the National Institutes of Health.
A characteristic property of several mRNA-based therapeutics, including BNT162b2 and
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mRNA-1273, is the use of lipid NPs as the first-line vehicles, facilitating endosomal escape
after their endocytosis and the release of their genetic cargo in the cytosol. The mRNA
is then translated into antigenic proteins (i.e., SARS-CoV-2 spike protein), promoting the
neutralization of antibody production by the immune system. Collectively, these lipid
nanocarriers would serve three essential purposes, namely, (i) maintenance of mRNA
conformation and stability, (ii) protection of mRNA cargos from degradation via the en-
dosomal escape, and (iii) efficient cellular uptake via the targeted mRNA delivery [34].
Even though BNT162b2 and mRNA-1273 would not be the first approved nanoformula-
tions for human use, the odds surrounding nanomedicine and the nano–bio interactions
remain understudied [36]. Previous reports have demonstrated the crucial role of some
nanotheranostic systems in rapid (i.e., 10 min) CoV diagnostics using Ag NPs [37] and
Au NPs [38] and efficient in vitro CoV inhibitory effects using carbon dots [39,40] and
Ag2S QDs [41]. A primary concern with nanotheranostics is human exposure; for example,
the exposure of researchers synthesizing the nanoparticles (NPs) and of consumers of
products containing NPs. There are several routes of exposure, dictating the trajectory
and fate of NPs [42]. Unfortunately, carrying out research directed towards understanding
the fate of NPs (in both humans and environments) and preventing the risks associated
with them remains highly unappealing in the highly competitive worlds of intellectual
property, research funding, and technology development [43] (i.e., anti-coronavirus NP
formulations). Nanotoxicology is a branch of science dealing with the interactions of
nanoparticles with biological systems, mapping the connections and interfaces between
chemistry (size, shape, composition, aggregation, surface charge, and surface functionali-
ties of NPs) and biology (induced toxic effects) [42] (as seen in Figure 1). While nanotoxicity
research has been flourished on in vitro cell culture models, there is still very little scientific
understanding of in vivo assessments of NPs because in vivo models are more complex
and sophisticated [44]. Rodents (mice and rats) and rabbits are popular animal vertebrate
models employed in toxicological studies because of their cheap costs and wealth of avail-
able information on their growth, reproduction, and toxicology corresponding to humans.
However, the hurdle remains in the slow embryonic development of rodents and rabbits.
Zebrafish (Danio rerio) embryos cross this hurdle as an animal model full of promise due to
(i) their short life cycle, (ii) embryo transparency, facilitating a reliable observation of toxic
effects, (iii) molecular accessibility for gene manipulation, constituting a homologous 85%
of protein-coding genes to human counterparts, and (iv) their short reproduction cycle and
high fecundity, enabling one female to produce 100 to 300 embryos. Despite the extensive
antibacterial administration of Ag NPs, their toxicological exploitation in zebrafish still
in an early stage [45]. A further in vivo complication lies in the fact that NP/biological
interactions and interfaces provoke various biocompatible or biodiverse effects in humans
and the environment concerning the distribution, metabolism, immune response, and
excretion of NPs [42].
With respect to more specific toxicities related to NPs, subchronically inflamed human
small airway epithelial cells exposed to metal oxide and copier center NPs are susceptible
to pneumonic nanotoxicity [44], which could be related to and may have contributed
to the COVID-19 pandemic, causing pneumonia, especially in immunocompromised
patients [46]. Inhalation of high levels of NPs (possessing ultra-high surface-to-volume
ratios and deposition rates in the lung alveoli) leads to a risk of developing respiratory and
cardiac diseases besides lung cancer [47]. The toxicity issues surrounding quantum dots
(QDs) are a disputed subject regarding their biomedical applications. These toxicity issues
and beliefs emerge from the toxicity of cadmium-containing QDs towards cultured cells,
with their toxicity towards humans and in all of their other forms being extrapolated on
the basis their being homogeneous materials. However, this extrapolation is refuted by
the lack of studies demonstrating such toxicities in animal models and the heterogeneity
of the unique physicochemical properties of various QDs [48]. Metal NPs ending in
the aquatic environment could be magnified in aquatic organisms such as fish through
the food chain. After human consumption of water or organisms containing these NPs,
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including vegetables, fish, and livestock, the metal NPs could eventually accumulate in the
human body, posing a threat to human health [45]. Despite this cumulative threat, research
investigating the toxic mechanisms of metal NPs in zebrafish (as an aquatic vertebrate
model) remains unsatisfactory [45].
Figure 1. The nanotoxicology of anti-coronavirus nanotheranostics (NTCs) connects the pieces (i.e.,
the chemistry of nanomaterials, interfaces, and biology) of the scientific jigsaw puzzle played by
humans in our shared environment in attempting to decipher their safety issues.
Consequently, this work will generate fresh insight into safety concerns (in vitro,
in vivo, and with respect to human and environmental exposures) and nano–bio interfaces
of anti-CoV nanotheranostics (as displayed in Figure 1). We mainly address the safety
issues concerning plasmonic NPs and QDs, which were discussed as promising antiviral
nanotheranostic systems in our previously accepted review article [49], investigating the
mechanistic actions of diagnosis and treatment with nanotheranostics in combating coron-
avirus infections. Other significant areas where this study makes original contributions
include: (i) garnering and interpreting the recent facts explored regarding SARS-CoV-2;
(ii) highlighting the SARS-CoV-2 human–animal interfaces that have been missing in liter-
ature; and (iii) exploring the realistic options of repurposed drugs and vaccines against
SARS-CoV-2. We finally pinpoint the challenges associated with implementing anti-CoV
nanotheranostics and our own inputs with respect to the next steps in this flourishing field
of anti-CoV NPs.
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2. Nano–Bio Interface
The unusual properties of NPs have a significant impact on the structure and function
of proteins, making it intriguing to advance the understanding of such effects and inter-
faces [50]. Therefore, it is fitting first to ask what is meant by nano–bio interfaces? Nano–bio
interfaces encompass the dynamic physicochemical interactions, kinetics, and thermody-
namic exchanges between the surfaces of NPs and biological components (e.g., proteins,
phospholipids, membranes, membrane-bound vesicles, organelles, DNA, biological fluids,
and urine) [51,52]. The nano–bio interface (as depicted in Figure 1) is best described as
comprising three interacting components: (i) the surface of NPs (characteristics dictated by
the physicochemical composition of NPs); (ii) the solid–liquid interface and the changes
associated with the interactions between NPs and the surrounding media; and (iii) the
contact zone of the solid–liquid interface with biological substrates [51].
The penetration of NPs into the biological fluid (e.g., blood, plasma, or interstitial
fluid) shapes a protein corona (PC). The characters of the PC formed would not only
depend on the physicochemical properties of NPs (i.e., size, shape, composition, surface
functional groups, and surface charges) and the biophysical properties of the biological
media (i.e., blood, interstitial fluid, or cell cytoplasm), but also on the protein–protein
interactions due to their competition to adsorb on the highly reactive NP surfaces [53].
NPs are decorated and coated with proteins, propelled by a potential energy gradient that
could undertake conformational changes. These changes expose new epitopes or altering
functions. Consequently, the PC frames a new biological identity for the NPs (e.g., surface
properties, charges, resistance to aggregation, hydrodynamic size, and composition of
PC) [51,52,54]. The life spans of NP–ligand complexes last from microseconds to days,
influenced by the protein concentrations in the vicinity of NPs, which differ from one
biological compartment to another [51]. Environmental factors, including temperature,
local heating, and incubation time, also influence PC composition [52]. However, the
specific time until which NP–ligand complexes exhibit biological significance remains,
unfortunately, a mystery [54]. Some tricky attempts could still be made to make sense
of this particular binding time, such as using a fixed quenching agent on the protein.
Or the protein adsorption to the NP could be traced via fluorescence decay [54]. The
PC architecture may be divided into (i) hard PC, representing the strong NP–protein
interactions achieved within seconds to minutes, and which is the closest layer to the
surface of the NPs; and (ii) soft PC, representing the loosely bound external layer of
protein–protein interactions achieved within hours [53,55]. Furthermore, the soft corona
proteins could also interact with the hard corona proteins during their desorption from
NP surfaces and empty a site for other biomolecular interactions. These hard and soft
PCs describe the nano–bio interface’s dynamic nature between NPs and proteins. This
dynamic nano–bio interface is governed by a series of interactions, namely hydrodynamic,
electrostatic, electrodynamic, solvent, and steric interactions. Such interactions can be
explained as follows: (i) hydrodynamic interactions, representing long-range (i.e., within
102 to 106 nm range) interactions between particles moving within a viscous fluid, transport,
shear, lift, and Brownian diffusions, increasing the collision between NPs and other surfaces
in the system; (ii) electrostatic interactions, which are Coulomb interactions (within 1 to
100 nm range) between charged interfaces and co-ions, forming an electrostatic double
layer; (iii) electrodynamic interactions (within 1 to 100 nm range), which are attractive Van
der Waals interactions; (iv) solvent interactions (within the smallest range of 10 to 10 nm),
which are those including lyophobic or lyophilic materials and solvent molecules; and
(v) steric interactions, which are those repulsive interactions (within 1 to 100 nm range)
with other interfaces resulting from the adsorbed polymers, increasing the stability of
individual NPs, while interfering in cellular uptake [53].
A critical general role of the PC is to tag NPs in order for them to be more recognizable
by innate immunity, quickly clearing the NPs via the phagocytic cells in the lungs, liver,
and spleen. Consequently, PCs express NP immunogenicity [55]. NP–membrane wrapping
describes the adhesion and engulfment of NPs in a cell surface lipid bilayer, which can
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be an advantage for therapeutic drug delivery purposes. This wrapping is governed
by specific (ligand–receptor, facilitating receptor-mediated endocytosis) and nonspecific
binding interactions guided by three prime characteristics of NPs (as displayed in Figure 2).
These are, namely, (i) surface charge, playing a crucial role in the interactions of NPs with
charged phospholipid groups or protein domains on cell surfaces, considering the more
robust effects of cationic surfaces than their anionic counterparts; (ii) hydrophobicity, where
hydrophobic NPs are more rapidly engulfed than their less hydrophobic counterparts,
because more hydrophobic surfaces are more reliable for aggregation, facilitating their
early removal by the reticuloendothelial system; and (iii) roughness, where the smaller NP
surface protrusions or depressions decrease repulsive interactions and enhance adhesion
and cellular uptake [51]. Deng and colleagues [56] demonstrated that the negatively
charged poly(acrylic acid)-conjugated gold NPs (GNPs, of size 5 nm) bind to specific sites on
fibrinogen (length of ~45 nm and diameter of 5 nm) and induce fibrinogen unfolding. This
unfolding is proinflammatory and provokes an integrin receptor (Mac-1) interaction. Mac-1
activation increases the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B
cells) signaling pathway and elegantly releases inflammatory cytokines in an alternative
mechanism rather than the traditional understood oxidative stress.
Figure 2. Interactions and forces between nanoparticles (NPs) and biological interfaces (i.e., protein corona, PC) with an
accompanying illustration of cellular endocytosis of SARS-CoV-2, which is also spherical and falls within the nanometer
range. Interactions and forces that occur at the contact of NPs with cells or upon suspension in biological media include
biomolecular interactions, repulsive electrostatic forces, attractive Van der Waals and depletion forces, and covalent
forces [51].
With respect to the nano–bio interface, it is vital to uncover the implications of the
‘Trojan-horse’ effect and the ‘aging’ of NPs. The ‘Trojan-horse’ effect is the active entrance
and internalization of small NPs into cells and organisms after unwitting recognition by cell
receptors, inducing toxicity [57,58]. The ‘aging’ of NPs is a new term describing the holistic
distinctive structural and chemical properties of aged NPs compared with their pristine
counterparts (as depicted in Figure 3). Regrettably, most studies in the nanotoxicology
field have only focused on pristine NPs, making it useless to correlate the toxicological and
environmental findings of pristine NPs to the aged ones [57].
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Figure 3. Aging of ceria nanoparticles (NPs). Different holistic properties of young (upper) and aged
(lower) ceria NPs after being released into the environment. Reprinted with permission from ref. [57].
Copyright, 2015, The American Association for the Advancement of Science.
3. In Vitro and In Vivo Biocompatibility Assessment of NPs
Plasmonic NPs are heavily employed for their promising surface plasmon resonance
(SPR) properties, allowing early plasmonic diagnostics and enhanced therapeutics. How-
ever, pure Ag NPs could be toxic, while also being easily aggregated due to their high
surface energy. Consequently, the surface functionalization of Ag NPs is a dominant
safety issue. Regarding Au NPs, biocompatibility is one of their intriguing properties,
facilitating wide applications, with colloidal particles ranging from 3 to 100 nm being
acceptably non-toxic in vitro, while Au NPs of 1 to 2 nm could constitute hazardous ef-
fects [59]. Au NPs are also biocompatible, as long as no charge is present, while positively
or negatively charged Au NPs induce toxicities [60]. Furthermore, QDs and are notable
examples of NPs showing no explicit biodegradation in vivo [42]. Therefore, this section
investigates the biocompatibility issues of mainly plasmonic NPs and QDs, and the factors
influencing them.
3.1. Assessment In Vitro
NP–cellular interaction affects the genomics, proteomics, and metabolomics of cells,
which could cause toxicities, resulting in apoptosis, necrosis, or autophagy. Different NP
toxicities fall under the following mechanisms: (i) plasma membrane damage disrupting
the permeability of ions; (ii) cytoskeleton modification reducing cellular proliferation and
motility; (iii) mitochondrial toxicity increasing mitochondrial membrane permeability and
inducing oxidative stress; (iv) nuclear damage, mainly executed by NPs < 5 nm, which
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can accumulate within the nucleus, interfering with cellular division; (v) reactive oxy-
gen species (ROS) generation inducing oxidative stress; and (vi) interference in signaling
pathways, including mitogen-activated protein kinase, NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells), bone morphogenic protein, and transforming growth
factor β, causing toxicity [61]. As the primary focus is integrating anti-coronavirus nanoth-
eranostic systems in facemasks, this section aims to clarify the consequences of accidentally
inhaling loose NPs from the masks into the lungs or the impact of occupational exposure
to such NPs on the lung cell lines as an investigation model.
With respect to the question of plasmonic NPs, Ng et al. [62] identified the effects of
Au NPs (20 nm) treating small airway epithelial cells (SAECs) on unexposed neighboring
MRC5 lung fibroblasts, inducing changes in protein expression in a co-culture system, imi-
tating the respiratory tract. This change was translated as a significant downregulation of
cell migration promoting proteins (e.g., plasminogen activator, urokinase, and chemokine
growth-regulated oncogene) and increased cell adhesion enhancing proteins (e.g., paxillin,
breast cancer anti-estrogen resistance 1 and caveolin-1). These protein alterations caused
phenotypic changes in lung fibroblasts (i.e., cytoskeleton remodeling and increased cell
adhesion), affecting lung function. In contrast to the adverse effects of Au NP previously
described on lung cells, Brandenberger et al. [63] detected no adverse effects of Au NPs
(15 nm) in a triple cell co-culture system, mimicking the alveolar lung epithelium, after
aerosol exposure at the air–liquid interface. The authors observed the homogeneous deposi-
tion and uptake of Au NPs into the cells without mRNA induction (i.e., of proinflammatory
markers, TNFα, IL-8, and inducible nitric oxide synthase, and oxidative stress markers,
hemeoxygenase-1, and superoxide dismutase 2). They ultimately recommended broader
chronic investigations using in vivo animal models to confirm the absence of adverse
effects before entering the nanomedicine market for various applications. In the case of
Ag NPs, Suliman et al. [64] investigated the toxicity of Ag NPs (56 nm) in human lung
epithelial (A549) cells. Ag NPs caused dose- and time-dependent cytotoxicity in A549
cells, as shown by MTT [3-(4,5-dimethylthiazol-2-yl)22,5 diphenyl tetrazolium bromide]
assay and the lactate dehydrogenase enzyme. Ag NPs induced dose- and time-dependent
changes in the following: (i) cell morphology, and (ii) oxidative stress via the depletion
of glutathione (i.e., antioxidant and the frontline of the cellular defense mechanism) and
elevated levels of lipid peroxides, superoxide dismutase, and catalase (i.e., antioxidant
enzymes), forming DNA adducts. The authors finally argued that Ag NPs induced cytotox-
icity and immunotoxicity facilitated mainly by ROS generation and oxidative stress. They
ultimately drew a note of caution with respect to industrial applications of Ag NPs. Two
further studies verified that biosynthesized Ag NPs showed dose-dependent cytotoxicity
against A549 cells as determined by MTT assay [65,66]. Gliga et al. [67] demonstrated
that small Ag NPs (10 nm) displayed a noticeable cytotoxic impact on human lung cells
(BEAS-2B) through intracellular Ag release. Ag NPs induced DNA damage with neither
γH2AX foci formation nor increased ROS production in BEAS-2B cells. Hamilton et al. [68]
also proved that smaller Ag NPs (20 nm), regardless of coating, showed greater toxicity in
lung epithelial cell lines than larger Ag NPs (110 nm). The toxicity was dependent on the
rate of particle dissolution, with the more enhanced and faster dissolution of smaller Ag
NPs eliciting more toxicity.
Considering QDs as anti-CoV candidates, Chen and colleagues [69] showed the cyto-
toxicity of indium phosphide/zinc sulfate (InP/ZnS) QDs (with different surface groups of
COOH, NH2, and OH and with hydrodynamic diameters of 9, 12, and 98 nm, respectively)
towards alveolar type II epithelial cells, RLE-6TN. Increasing the concentrations of InP/ZnS
QDs decreased the cell viability after 48 h, with the highest toxicity being recorded for
InP/ZnS-COOH QDs followed by InP/ZnS-NH2 QDs, and finally InP/ZnSOH QDs (as
shown in Figure 4). All InP/ZnS QDs promoted cell apoptosis after 48 h and increased
ROS levels and oxidative stress after being internalized within the cells. This induced
apoptosis and oxidative stress implies that caution should be exercised when adjusting the
administered concentrations and surface functional groups of InP/ZnS QDs in theranostics.
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These results differ from those of Buz and co-workers [70]. The latter showed the absence
of toxicity of N-acetyl-L-cysteine (antioxidant)-Ag2S QDs (with a size of 1 to 5 nm and
strong emission between 748 and 840 nm, as well as sufficient stability in biological media)
towards BEAS-2B (human bronchial epithelial cells) even with the high internalization,
implying their cytocompatibility [70].
Figure 4. Cell viabilities of RLE-6TN cells after treatment with quantum dots (QDs). Namely, InP/ZnS-COOH, InP/ZnS-
NH2, and InP/ZnS-OH QDs for 24 (A) and 48 h (B). Adapted from [69] under the terms of the Creative Commons Attribution
License (CC BY); Frontiers Media SA, 2018.
3.2. Assessment In Vivo
In the current work, we aim to thoroughly investigate the in vivo toxicity of promising
anti-coronavirus nanotheranostics on different animal models, including rats, mice, and
zebrafish embryos (i.e., the prime focus of in vivo toxicity assessment of the present review
article). Starting the assessment with rats and mice, serum amyloid A (SAA) and C-reactive
protein (CRP, a nonspecific acute-phase protein produced by hepatocytes of 0.8 mg/L
concentration in normal individuals, with higher levels associated with inflammation and
tissue damage [71]) levels are predictors of risk of coronary heart disease. However, rats do
not express Saa genes, and mice only moderately express Crp genes [47]. The architecture
of the mouse trachea is similar to its human counterpart. The mouse airways and the
smallest bronchioles of humans are covered by cuboidal epithelium, lacking basal cells and
containing ciliated, secretory, and neuroendocrine cells. The alveoli of mice and humans
share a similar composition with two functionally distinct cell types: (i) flat and extended
alveolar type I (AT-I) cells allow gas exchange; and (ii) cuboidal alveolar type II (AT-II)
cells allow surfactant protein production and secretion [72]. Lin et al. [73] examined the
acute toxicity of InP/ZnS QDs (with different surface modifications, including COOH,
NH2, and OH, and hydrodynamic diameters of 10, 14, and 104 nm, respectively) in mice
after pulmonary aerosol inhalation at a dosage of 2.5 mg/kg or 25 mg/kg. InP/ZnS
QDs entered circulation and accumulated in the lungs and kidneys. This entrance and
accumulation caused (i) immunological response via decreased lymphocyte and increased
granulocyte counts; (ii) labeling of lung tissue and hyperemia in alveolar septa (i.e., lung
injury, especially for the QDs with NH2 surface groups); and (iii) decrease in alkaline
phosphatase and globulin, indicating the accumulation of adverse effects in the interference
of organ functions. The authors again advised exercising caution in adjusting the surface
modifications of QDs to reduce their toxicities in vivo in biological applications.
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Let us connect the factors influencing the toxicity of NPs in zebrafish embryos within
a single storyline by answering the following questions. Would the size of NPs govern
their toxicity in zebrafish? Liu et al. [74] demonstrated the size-dependent toxicity of NPs
using the same surfactant (PVP). The smaller Ag NPs (20 nm) were more toxic to zebrafish
after 96 h exposure than larger ones (100 nm). This greater toxicity was determined on the
basis of a decrease in the 96-h LC50 (median lethal concentration) from 1.34 to 2.57 mg/L.
They explained the greater toxicity as being a result of the greater ability of smaller Ag
NPs to enter cells compared to the aggregated larger ones. The authors demonstrated
this greater toxicity on the molecular level by showing the higher expression levels of
nine genes specifically expressed for gills (first entrance point of Ag NPs to zebrafish),
intestines (digestive and absorptive point to Ag NPs), and muscles with the smaller Ag
Nps compared to the larger ones. Another explanation for the size-dependent toxicity of
Ag NPs is related to the fact that smaller Ag NPs have the ability to diffuse more into the
embryos than larger particles because of the inverse correlation of the diffusion coefficient
of single Ag NPs and their size [75]. A further reason for the greater toxicity of smaller Ag
NPs (20 nm) compared to larger Ag NPs (110 nm) in zebrafish embryos was attributed to
the particle dispersion and the release of Ag+ ions, which goven the toxicity of Ag NPs [76],
while smaller Ag NPs release more Ag+ ions more quickly [77,78].
Turning now to the NP shape factor, what would its toxic influence be on zebrafish?
Generally speaking, spherical NPs are more efficiently internalized by cells than rod-
shaped or filamentous particles because of the ease with which the cellular membrane
wraps around spherical NPs, decreasing their circulation time in vivo [61]. Explicitly speak-
ing, Abramenko et al. [79] demonstrated the greater toxicity (lower LC50) of Ag nanoplates
(0.0415 LC50 with a size of 28 nm in the egg water) than that of Ag nanospheres (0.0169 LC50
with a size of 51 nm in the egg water) and Ag+ ions (0.0649 LC50) in zebrafish embryos. The
authors explained their observation as being a result of the increased surface energy and
the quasi-stable state of the anisotropic nanoplates. However, we remain skeptical about
the toxicity observed being a result of the shape of the NPs in the earlier study, owing to
the size difference reported between the smaller nanoplates and the larger nanospheres.
Another study [80] presented a concrete explanation for the greater toxicity of the Ag
nanoplates (32 nm) (i.e., hitting 100% mortality of zebrafish embryos at a concentration of
only 10 µg/mL) compared to that of spherical Ag NPs (10, 20, and 40 nm). The higher toxi-
city was attributed to the increased surface reactivity of Ag nanoplates due to their crystal
defects (i.e., the irregular stacking planes of atoms in the crystal lattice). Excitingly, the au-
thors concluded two facts: (i) the surface reactivity of the Ag nanoplates drives a different
toxicity mechanism from that of the Ag nanospheres; and (ii) the refutation of the belief
that the release of Ag+ ions from the surface of NPs is the main reason behind their toxicity,
because even Ag nanoplates released fewer Ag+ ions than Ag nanospheres in Holtfreter’s
media, and they induced greater toxicity. Sangabathuni and colleagues [81] avoided the
size difference in investigating the shape-dependent toxicity of Au NPs by almost unifying
the sizes of rod-shaped Au NPs (49 nm) and star-shaped Au NPs (46 nm) (as shown in
Figure 5). They observed an initial accumulation (after 4 h) of rod Au NPs, followed by a
clearance from adult zebrafish (injected intraperitoneally) after 24 and 48 h. In contrast,
star Au NPs showed a steady cumulative state and prolonged sequestration (as shown in
Figure 5). They attributed this discrepancy to the difference in the physical factors of the
different shapes of NPs, such as the aspect ratio of rod Au NPs facilitating their rapid
uptake and clearance, while the high friction coefficient of star Au NPs facilitated their slow
clearance. Regarding NP surface charge, would it also impact NP toxicity? Truong et al. [82]
revealed that Au NPs of the same size (1.5 nm) and concentration (50 µg/mL) had different
impacts on the larval behavior of zebrafish based on the surface charge of their functional
groups. Negatively charged 2-mercaptoethanesulfonic acid-Au NPs decreased the larval
locomotor activity (i.e., distance swam by larvae) in the dark by 50% less than that of the
neutral 2-(2-(2-mercaptoethoxy)ethoxy)ethanol-Au NPs, which were similar to the control
group. Now the most conflicting question is what the main reason behind the toxicity
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of NPs is. Is it the Ag+ ions released from NPs? Or NPs themselves? Osborne et al. [83]
demonstrated that Ag+ are the critical factor responsible for the toxicity of Ag NPs (35 nm,
LC50 of 500 µg/L) in zebrafish embryos, especially at the gastrula stage (embryonic de-
formity at the 1 to 2 cell stage) with more expression of the heavy metal stress response
gene (metallothionine 2) in this stage (i.e., 7.2 h post-fertilization, hpf) compared with after
24 hpf. This outcome is contrary to our previous results [84], which showed a greater
toxicity (higher degree of mortality) to be induced by Ag NPs (9 nm) than by Ag+ in the
form of AgNO3 due to the complexation of Ag+ with Cl- when exposed in Holtfreter’s
medium, decreasing the bioavailable exposure to Ag+. Moreover, the reported phenotypic
toxicity of Ag NPs was entirely different from that of AgNO3 NPs. Ag NPs induced axial
deformity, whereas AgNO3 induced deposition of Ag+ on the embryonic chorions.
Figure 5. SEM images (1) of different shapes of Au NPs. Namely, spherical Au NPs (a), rod Au NPs (b), and star Au NPs (c).
Confocal images (2) of zebrafish digestive system after injection with Fluorescein-conjugated glyco-Au NPs after different
time points. Namely, spherical Au NPs after 4 h (a,f) (with slightly different sizes); rod Au NPs after 4 h (b,g) (with slightly
different sizes), 24 h (d), and 48 h (e); and star Au NPs after 4 h (c,h) (with slightly different sizes), 24 h (i), and 48 h (j).
Reproduced from [81] under the terms of the Creative Commons Attribution 4.0 License with modifications; Springer
Nature Limited, 2017.
What could the administration of such NPs to humans induce? Human poisoning
from Ag NPs and Ag+ ions has been demonstrated to be argyria (i.e., a blueish-grey dis-
coloration of the skin induced by silver deposits). Additionally, the outcome of studies
remains controversial with respect to Ag crossing the blood–brain barrier, and penetrating
the extracellular fluid of the brain after oral administration. Other data refute the crossing
of the blood–brain barrier by Ag [85]. A 62-year-old male was diagnosed with argyria
with uniform blue-gray pigmentation on his head, neck, chest, and limbs. Within the
sun-exposed region, conjunctiva, caruncle, and lunula of nails were also affected. The pig-
mented asymptomatic lesions developed within five years following weekly consumption
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of a bottle of AgNO3 by the patients after reading a publication describing the benefits
of AgNO3 ‘in killing microorganisms’. The histopathological evaluation of the patient’s
incisional biopsy demonstrated scattered extracellular black granules among collagen fibers
that were also confirmed by electronic microscopy, showing the same dark brown pigmen-
tation. The sun-exposed region’s discoloration was attributed to the photoactivation and
metal reduction of the large amounts of Ag in such areas [86]. Moreover, even occupational
exposure to NPs increases the systemic acute phase response. This is a long-term response
for insoluble NPs, corresponding to a 45-year work-life [47]. These concerns regarding
occupational exposure were highlighted in a previous case study, which demonstrated the
high exposure level of apprentice welders to ultrafine particles (UFPs, with a size of 50 to
214 nm, with a majority of particles < 100 nm) that could ultimately result in the develop-
ment of respiratory symptoms. UFP exposures and particle sizes were influenced by the
type of welding process and welded metal and the time elapsed from the previous final
welding [87]. Even though the focus of the present manuscript is on anti-CoV plasmonic
NPs and QDs, titanium dioxide (TiO2) NPs remain one of the most widely used NPs, can
rapidly penetrate the skin, and are poorly eliminated, inducing severe skin damage [88].
Monsé and co-workers [89] investigated the effect of inhaling airborne ZnO NPs in sixteen
healthy nonsmoking volunteers for 4 h. ZnO NP concentrations of 0.5, 1, and 2 mg/m3 and
sizes of 48, 63, and 86 nm, respectively, demonstrated significant concentration-dependent
increases in acute phase proteins (CRP and SAA) and neutrophils in the blood of subjects
exposed to concentrations of 1 and 2 mg/m3 of ZnO NPs. The authors then proposed a
level of 0.5 to 1 mg/m3 ZnO NP to describe the No Effect Exposure Level (NOEL). Ulti-
mately, we urge the scientific community to undertake further investigations, disclosing
the possible adverse effects of different plasmonic NPs and QDs on human bodies.
4. What Safety Challenges Do Anti-CoV NPs Present?
Despite the tremendous number of publications dedicated to investigating the eco-
toxicological effects of NPs on humans or in animals or cell cultures, most of these studies
do not offer clear-cut statements on the safety of NPs. Conversely, they are mostly con-
tradictory or mechanistic studies rather than toxicological ones [90]. A potential problem
concerning NP toxicity is the multiple factors determining the NP toxicity, including
chemical composition, particle size, shape, surface charge, and other physicochemical
properties [45], for example, the thorough examination of spherical Ag NPs at the expense
of other shapes overlooked by researchers. This spherical Ag NP shape almost lacks crystal
defects that could be present in the understudied Ag nanoplates [80]. This problem is
also exacerbated by the different synthesis procedures, raw materials, and reaction crite-
ria needed to produce adequate volumes of uniform NPs with reproducible properties
obtained across diverse research groups [42]. This irreproducibility extends to complex
nanobiotechnology systems, raising the conflict within the literature to unprecedented
levels [91]. To complicate the concerns surround NP safety, there is not even consensus
regarding the assessment measurements concerning human and occupational exposure to
NPs and UFPs [87]. Other general drawbacks of vaccines utilizing nanotechnology include
the challenging cold chain requirements, which constitute a significant financial hurdle to
the availability of such life-saving vaccines in developing nations [35].
Despite the tremendous amount of research conducted on the formation of NP-PCs,
most of these studies have only been executed in vitro, failing to represent the complex
in vivo environment, which constitutes a challenge to the capture of NPs after their ad-
ministration in vivo. Another challenge that strikes at the heart of the NP-PC debate is
the dynamic nature of physiological fluids (e.g., the flow of blood at different velocities,
ranging from a few µm/s in capillaries to 60 cm/s in the ascending aortas), which elicits
shear stress on NPs and results in new biomolecules [52]. Furthermore, far too little in-
formation and attention have been paid to the soft PC compared to the massive extent of
investigations into hard PC [55]. An ironic fact is that proteins are not the sole biological
entity interacting with NPs. The binding of lipids, such as plasma lipoproteins on NPs, has
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also been discussed in the literature [55]. To date, there is little agreement on the in vitro
and in vivo toxicity findings for QDs, which could be explained by the precise dosages
warranted under cultural conditions and the varying dosages maintained in vivo [48].
Another perceived problem with investigating the biological effects of NPs is their particle
agglomeration under exposure conditions [80]. To date, there remains a lack of consensus
on basic laboratory protocols within the infant nanotoxicology field [57].
On the one hand, assays for CRP are commercially available and commonly used
as systemic inflammation biomarkers. On the other hand, these assays are fraught with
caveats, because many factors influence the CRP levels, including body mass index, smok-
ing, chronic inflammatory diseases, anti-inflammatory drugs, and infections [47]. For
example, elevated CRP levels support the differential diagnosis of acute bacterial infec-
tions [92]. Recent work by the Wuhan team [93] concluded that serum levels of CRP
could be used independently to assess and predict the severity of COVID-19. Among the
140 investigated COVID-19 patients, 91 (65%) patients showed increased CRP levels, and
these were more significant in the severe group than the mild group. The authors drew a
roadmap, indicating that patients with CRP > 41.8 mg/L were more prone to developing
severe COVID-19 illness.
It is prudent to choose a suitable animal model for the investigation of emerging
anti-CoV drugs. One reason behind the importance of animal model selection is that a
small animal, for example, BALB/c and C57BL/6 mice, golden Syrian hamsters, and ferrets,
could be infected with SARS-CoV without showing the disease clinically. Additionally,
small BALB/c mice and golden Syrian hamsters are not susceptible to MERS-CoV infection.
Rhesus macaques, a non-human primate, only develop self-limiting disease. By contrast,
the most appropriate animal models for testing anti-SARS-CoV technologies are transgenic
mice expressing human ACE2. The chief constraint remains the limited availability of these
ACE2-transgenic mice [1]. With respect to SARS-CoV-2 specifically, the spike (S) glycopro-
tein includes the surface unit S1, which binds to ACE2 receptors. The transmembrane unit
S2 is cleaved by human transmembrane serine proteases TMPRSS1 and TMPTSS2, making
the co-expression of ACE2 and TMPRSSs crucial for SARS-CoV-2 infection. However, rats,
mice, rabbits, and guinea pigs lack ACE2 receptors. In contrast, non-human primates,
Syrian hamsters, ferrets, cats, and engineered chimeras, can mimic human infections and
are promising animal models of SARS-CoV-2 infections. The challenges lie in the addi-
tional ethical justifications required to deal with non-human primate animal models, the
scarcity of biosafety level III facilities, and the lack of trained personnel for executing such
experiments [94].
5. Our Inputs: What Next?
A recent study [95] attributed the main reason behind severe COVID-19 to the progres-
sive damage of lung epithelial–endothelial barriers, facilitating wide viral dissemination
and spread. This endothelial damage could stem from the heightened immune responses
mediated via complement activation, antibody-dependent enhancement, and cytokine
release. The authors then highlighted the necessity of identifying COVID-19 patients in the
early infectious phases and testing antiviral therapies at these phases to prevent viral entry
and replication. Therefore, we believe that the integration of antiviral nanotheranostics
into facemasks would achieve two goals. Firstly, they would inactivate viral particles,
preventing their entry into the upper respiratory tract and avoiding even early phases of
infections. Secondly, the safety issues associated with the nanoparticles involved would be
reduced, as they are integrated within the facemasks. However, studies should be executed
to show the absence of NP or ion leaching from the masks and investigate the consequence
of NP inhalation from the masks into the lungs.
Regrettably, several intriguing treatment strategies failed to reach evaluation or reg-
istration after clinical trials during the previous SARS-CoV-1 and MERS-CoV outbreaks
because of delays and the declining number of infected cases [2]. Furthermore, the host
immune response to infection activates the coagulation cascade, where thrombin receptors
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(i.e., proteinase-activated receptors, PARs, chiefly PAR-1) facilitate an entwined relation-
ship between coagulation, inflammatory, and fibrotic responses. This relationship shapes
the lung pathology associated with COVID-19 [3]. Consequently, suppressing the ex-
cessive inflammatory response triggered by COVID-19 could have an invaluable impact
on decreasing the death toll of severely ill patients [96]. The harmful effects of cytokine
storms on the poor prognosis of COVID-19 call for other treatment methodologies targeting
the cytokine storm, such as artificial-liver blood purification [96]. Even though concerns
still revolve around the possible complications of steroids when treating COVID-19 pa-
tients, it makes no sense to delay administering a widely available and affordable drug,
demonstrating reduced mortalities, especially in ventilated COVID-19 patients [97]. For
other repurposed drugs, the FDA released a letter on 10 April 2020 [98] warning the pub-
lic against self-medication using ivermectin products intended for treating animals (i.e.,
against heartworm diseases and certain parasites). The reason behind this concern is that
the FDA has only assessed their safety and effectiveness in the intended animal species.
Therefore, people should not use animal medications, because they could be hazardous to
humans, unless an ivermectin form has been prescribed for people by a licensed health
care provider and is obtained via a legitimate channel.
Regarding the human–animal interface of SARS-CoV-2 outbreaks, on the one hand, the
reason behind the efficient SARS-CoV-2 spread between mink farms could be as simple as
the high stocking animal densities on such farms. On the other hand, the in-depth reasons
behind this efficient spread remain ambiguous, making it difficult to stop the outbreak
among farms. A possible explanation for this rapid viral spread is that it is transmitted
through infected humans, fomites, infectious animal droplets, or contaminated dust [13].
However, the implementation of strict preventative measures in the Netherlands did not
stop the outbreak. Therefore, other reasons, such as wild animals and wind, should also
be considered. Regardless of the transmission route, halting the spread between farms
could be tricky because of the difficulty to control the movement of wild animals and the
dissemination of asymptomatic human cases. Furthermore, farming conditions, including
many different animals, constitute a risk of forming virus reservoirs and new mutations, as
well as the spread of the virus into communities from farms through humans or escaped
mink. Several other animals could also be SARS-CoV-2 infected, including raccoon dogs
that, just like mink, are bred in farms (in a few countries) and live in the wild close to
humans, even though no similar outbreaks have been detected among them yet. As it seems
a daunting task to fully control the viral spread among companion animals, another hurdle
is presented by limited resources, preventing the comprehensive administration of vaccines
to animals, despite the importance of vaccinating susceptible animals (i.e., minks, cats, and
zoo animals) [21]. We stress the necessity of regular, comprehensive animal surveillance
and monitoring, specifically for minks, raccoon dogs, cats, and zoo animals, to avoid and
predict SARS-CoV-2 human–animal and animal–human transmissions. Moreover, we
agree with systemic genotyping recommendations and sharing the genome sequences of
isolated SARS-CoV-2 strains from all infected animals to rapidly identify possible clusters
and related variants. The world is now in a situation where One Health preparedness and
response strategies are a must to synchronize efforts from different sectors (i.e., human
health, animal health, and agriculture) in order to achieve a timely control strategy against
the pandemic [12]. Additionally, we recommend further investigations on the UK and
South African variants. Such further investigations would elucidate the role of mutations
on several levels, including (i) the increased SARS-CoV-2 transmissibility, (ii) their effect on
the potency of vaccine candidates, and (iii) the possibility of SARS-CoV-2 re-infectivity on
both previously confirmed COVID-19 patients and vaccinated individuals.
To provide elucidative clues on the nebulous toxicity of NPs and the correlation be-
tween their size and the elicited toxicity, the nanotoxicology community should develop a
roadmap for standardized and harmonized toxicological testing procedures and methods
for NPs [57]. Defining the affinity, stoichiometry, kinetics, and concentrations of NPs is a
must for predicting their specific interactions with proteins to efficiently administer anti-
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coronavirus NPs in delivery systems. The dilemma remains in describing the contribution
of PCs to ultimate distribution of such nanosystems in vivo [53]. Computational models
using standard languages could also serve the prediction of NP toxicities [57] and help
understand the impact of PC structure and fingerprints (protein patterns of NPs character-
izing their PC) on cellular uptake and toxicity [52]. Development of research monitoring
for airborne NP exposure (i.e., aerosol samplers in workplaces and environments), detec-
tors for waterborne NPs, and sensors for measuring both exposure and potential hazards
(e.g., production of reactive oxygen species) under different circumstances could robustly
contribute to unveiling the impact of NPs on humans and the environment [43].
Several routes could mitigate the toxicity of NPs, including (i) inducing the aggrega-
tion of NPs using natural NPs that aggregate and immobilize engineered NPs at disposal
sites. (ii) Surface coating of NPs using stable, environmentally friendly, or degradable
coatings to avoid the adverse biological effects of NPs and their dissolution into toxic
ions. (iii) Modifying the surface charge of NPs (e.g., using layer-by-layer coatings of
polyelectrolytes) to reduce the cellular uptake and toxicity of NPs [51]. High-throughput
approaches, such as the quantitative structure–activity relation (QSAR, describing the
correlations between the physicochemical properties and bioactivity of NPs), are perceived
as promising tools for elaborating the interactions at the nano–bio interface and embrace
the assumption that NPs with correlated physicochemical properties induce similar biore-
sponses [52]. In the same vein, a previous report focusing on the toxicity of metallic NPs
in zebrafish embryos concluded that the size of the NPs was as crucial in determining
the toxicity of NPs as their chemical composition [45]. We refute this notion, because all
different factors that induce different physicochemical properties of NPs influence the final
toxicities of NPs. We believe that the size of NPs is a dominant feature in determining
the toxicity issues of nanotheranostics and the antimicrobial properties of NPs [84,99].
Consequently, we recommend that any study implemented to study the toxicity issues
of one of the physicochemical properties of NPs (e.g., the shape of NPs) should render
all of the other physicochemical properties uniform (e.g., size, surface charge, and purity
and chemical composition of NPs) and control the experimental procedures precisely in
order to be able to draw concrete conclusions and perform a faithful elaboration regarding
toxicity concerns. This is crucial, because any minor changes in the properties of NPs could
induce large differences in the biological responses [60].
Elucidating the safety of NPs and NP formulations would result in a great increase
in faith, maximizing public confidence and the reliable commercialization of such NPs or
NP formulations. Nanoinformatics, considering FAIR (Findable, Accessible, Re-usable,
and Interoperable) data principles, ensure nanosafety assessment. Nanoinformatics would
achieve this assessment by predicting NP properties, nano–bio interfaces, NP transfor-
mations, and biological impacts, together with in silico approaches, in order to ensure
the safety of NPs [100]. Recent technologies, namely organs-on-a-chip, mimic the in vivo
environments and biological responses of entire organs via multichannel 3D microfluidic
cell culture chips, and could traverse the gap between in vitro and in vivo studies by deci-
phering the PC dilemma [52]. Five years ago, the group of Zumla [1] recommended the
development of novel, broad-spectrum, pan-CoV antiviral drugs effective against different
CoVs as a “holy grail” treatment strategy against emerging CoV infections. Nowadays,
dreams are coming true, and BNT162b2 and mRNA-1273 nanoformulation vaccines are
close to receiving approval from the US Food and Drug Administration for human use [36].
During the final stages of submitting this manuscript, the vaccine had already been ap-
proved. After receiving the vaccination, the question is, for how long w the vaccine remain
potent? What are the accurate percentages surrounding possible re-infection after being
vaccinated? Would developing countries receive a sufficient share of the vaccine, money-
wise and storage-wise? Some outside-the-box solutions for the required cold chain hurdle
have been proposed, including vaccine delivery platforms and devices overcoming such
hindrances in order to make COVID-19 vaccines equally available for developed and devel-
oping nations [35]. Additionally, some endeavors for decreasing the overwhelmingly high
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costs of cold shipment chains (reaching almost 80% of the total cost of vaccine development)
have been undertaken through the collaboration of Suzhou Abogen Biosciences, Walvax
Biotechnology, and People’s Liberation Army Academy of Military Sciences in China for
COVID-19, developing a thermostable mRNA nano-vaccine. This vaccine candidate (i.e.,
ARCoV) is formed using the vesicle method, encapsulating the mRNA encoding the RBD
of SARS-CoV-2 S glycoprotein in the lipid NPs [34]. What remains a worrying concern
is the safety issues of NP formulations, as the whole nanotoxicity field is still in its early
stages. Many research gaps need to be filled before using nanomedicine in comprehensive
administrations in order to understand and predict the consequences of NPs scientifically
and to guarantee an end to reasonably escalating public concern. We enthusiastically recom-
mend engagement between multidisciplinary fields of virology, medicine, pharmacology,
chemistry, nanotechnology, and toxicology, together with the industrial sectors under
the umbrella of the WHO, to provide scientific, credible, and commercially and publicly
transparent data on the consequences of administering anti-coronavirus NP formulations.
6. Conclusions
The present manuscript sheds significant light on the recent discoveries associated
with SARS-CoV-2. We highlight the new SARS-CoV-2 variants, new cell entry mechanisms
via neuropilin-1 co-factor, and olfactory transmucosal route to the CNS, inducing neuro-
logical symptoms and explaining the loss of taste and smell associated with SARS-CoV-2.
We spot the overlooked SARS-CoV-2 human–animal and animal–human transmission
areas to further exclude a saddening wide animal culling. Instead, we suggest parallel
vaccination strategies for humans, minks, raccoon dogs, cats, and zoo animals using the
NP formulations of the BNT162b2 and mRNA-1273 vaccines. We call for further studies
on the UK and South African variants to unravel the role of mutations in transmissibility,
vaccine candidate efficacy, and the re-infectivity of SARS-CoV-2.
We express our skeptical opinion regarding the comprehensive administration of such
antiviral nanotheranostics in facemasks and NP formulations because of reported toxicities
and the different NP parameters that need be closely studied and tightly controlled to avoid
resulting biological toxicity. We raise an alarm bell with respect to the NPs employed in
antiviral nanotheranostics, as more studies in multidisciplinary fields should be executed
in order to clarify the odds surrounding infantile nanotoxicology for safe administration
and public relief.
We suggest the administration of antiviral nanotheranostics on surfaces for the detec-
tion and self-inactivation of SARS-CoV-2, considering that investigations should first be
performed on the toxicities of such systems on skin cells as a paradigm representing the
contact of skin with surfaces containing anti-coronavirus NPs. This hot topic is currently
under investigation in our experimental research agenda.
Author Contributions: D.A.M. conceptualized the work. D.A.M. collected authoritative scientific
research articles under the supervision of M.E. and T.S. D.A.M. wrote the manuscript, analytically
interpreted the literature, and drew the original Figures’ main sketches under T.S.’s supervision.
All the authors revised the manuscript with merited contributions offered by J.V. and W.H. R.K.
constructed the original and reprinted Figures. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: Open access funding provided by University of Helsinki.
Conflicts of Interest: The authors declare no conflict of interest.
Nanomaterials 2021, 11, 796 20 of 24
Abbreviations
Angiotensin-converting enzyme 2 ACE2
C-reactive protein CRP
cationic amphiphilic drugs CADs





median lethal concentration LC50
Middle East respiratory syndrome coronavirus MERS-CoV
neuropilin-1 NRP1
nuclear factor kappa-light-chain-enhancer of activated B cells NF-kB
open reading frames ORFs
protein corona PC
proteinase-activated receptors PARs




serum Amyloid A SAA
severe acute respiratory syndrome coronavirus 2 SARS-CoV-2





1. Zumla, A.; Chan, J.F.W.; Azhar, E.I.; Hui, D.S.C.; Yuen, K.Y. Coronaviruses-Drug Discovery and Therapeutic Options. Nat. Rev.
Drug Discov. 2016, 15, 327–347. [CrossRef] [PubMed]
2. Zumla, A.; Hui, D.S.; Azhar, E.I.; Memish, Z.A.; Maeurer, M. Reducing Mortality from 2019-NCoV: Host-Directed Therapies
Should Be an Option. Lancet 2020, 395, e35–e36. [CrossRef]
3. Jose, R.J.; Manuel, A. COVID-19 Cytokine Storm: The Interplay between Inflammation and Coagulation. Lancet Respir. Med. 2020,
8, e46–e47. [CrossRef]
4. Rowley, A.H. Understanding SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children. Nat. Rev. Immunol. 2020,
20, 453–454. [CrossRef] [PubMed]
5. Van Doremalen, N.; Bushmaker, T.; Morris, D.H.; Holbrook, M.G.; Gamble, A.; Williamson, B.N.; Tamin, A.; Harcourt, J.L.;
Thornburg, N.J.; Gerber, S.I.; et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med.
2020, 382, 1564–1567. [CrossRef]
6. Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; van der Meer, F.; Kallio, K.; Kaya, T.;
Anastasina, M.; et al. Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity. Science 2020, 2985, 1–9. [CrossRef]
7. Meinhardt, J.; Radke, J.; Dittmayer, C.; Franz, J.; Thomas, C.; Mothes, R.; Laue, M.; Schneider, J.; Brünink, S.; Greuel, S.; et al.
Olfactory Transmucosal SARS-CoV-2 Invasion as a Port of Central Nervous System Entry in Individuals with COVID-19. Nat.
Neurosci. 2020, 24, 168–175. [CrossRef]
8. Plante, J.A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B.A.; Lokugamage, K.G.; Zhang, X.; Muruato, A.E.; Zou, J.; Fontes-Garfias, C.R.; et al.
Spike Mutation D614G Alters SARS-CoV-2 Fitness. Nature 2020. [CrossRef]
9. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; et al. A New Coronavirus
Associated with Human Respiratory Disease in China. Nature 2020, 579, 265–269. [CrossRef]
10. Wang, Y.; Mao, J.-M.; Wang, G.-D.; Qiu, Z.; Yao, Q.; Chen, K.-P. Human SARS-CoV-2 Has Evolved to Reduce CG Dinucleotide in
Its Open Reading Frames. Sci. Rep. 2020, 10, 12331. [CrossRef]
11. Oude Munnink, B.B.; Sikkema, R.S.; Nieuwenhuijse, D.F.; Jan Molenaar, R.; Munger, E.; Molenkamp, R.; van der Spek, A.; Tolsma,
P.; Brouwer, M.; Bouwmeester-Vincken, N.; et al. Transmission of SARS-CoV-2 on Mink Farms between Humans and Mink and
Back to Humans. Science 2020, 371, 172–177. [CrossRef] [PubMed]
12. European Centre for Disease Prevention and Control (ECDC). Detection of New SARS-CoV-2 Variants Related to Mink; ECDC:
Stockholm, Sweden, 2020.
13. Oreshkova, N.; Molenaar, R.J.; Vreman, S.; Harders, F.; Oude Munnink, B.B.; Van Der Honing, R.W.H.; Gerhards, N.; Tolsma, P.;
Bouwstra, R.; Sikkema, R.S.; et al. SARS-CoV-2 Infection in Farmed Minks, the Netherlands, April and May 2020. Eurosurveillance
2020, 25, 1–7. [CrossRef] [PubMed]
Nanomaterials 2021, 11, 796 21 of 24
14. OIE Events in Animals: World Organisation for Animal Health. 2021. Available online: https://www.oie.int/en/scientific-
expertise/specific-information-and-recommendations/questions-and-answers-on-2019novel-coronavirus/events-in-animals/
(accessed on 6 January 2021).
15. Koopmans, M. Comment SARS-CoV-2 and the Human-Animal Interface: Outbreaks on Mink Farms. Lancet Infect. Dis. 2021,
3099, 18–19. [CrossRef]
16. Rabalski, L.; Kosinski, M.; Smura, T.; Aaltonen, K.; Kant, R. Detection and Molecular Characterisation of SARS-CoV-2 in Farmed
Mink (Neovision Vision) in Poland. bioRxiv 2020. in preprint. [CrossRef]
17. Hobbs, E.C.; Reid, T.J. Animals and SARS-CoV-2: Species Susceptibility and Viral Transmission in Experimental and Natural
Conditions, and the Potential Implications for Community Transmission. Transbound. Emerg. Dis. 2020, 1–18. [CrossRef]
18. Hammer, A.S.; Quaade, M.L.; Rasmussen, T.B.; Fonager, J.; Rasmussen, M.; Mundbjerg, K.; Lohse, L.; Strandbygaard, B.; Jørgensen,
C.S.; Alfaro-Núñez, A.; et al. SARS-CoV-2 Transmission between Mink (Neovison vison) and Humans, Denmark. Emerg. Infect. Dis.
2021, 27, 547–551. [CrossRef]
19. Mallapaty, S. COVID Mink Analysis Shows Mutations Are Not Dangerous—Yet. Nature 2020, 587, 340–341. [CrossRef] [PubMed]
20. Freuling, C.M.; Breithaupt, A.; Müller, T.; Sehl, J.; Balkema-Buschmann, A.; Rissmann, M.; Klein, A.; Wylezich, C.; Höper, D.;
Wernike, K.; et al. Susceptibility of Raccoon Dogs for Experimental SARS-CoV-2 Infection. Emerg. Infect. Dis. 2020, 26, 2982–2985.
[CrossRef]
21. Abdel-Moneim, A.S.; Abdelwhab, E.M. Evidence for SARS-COV-2 Infection of Animal Hosts. Pathogens 2020, 9, 529. [CrossRef]
22. Mahase, E. Covid-19: Low Dose Steroid Cuts Death in Ventilated Patients by One Third, Trial Finds. BMJ 2020, 369, m2422.
[CrossRef]
23. Lester, M.; Sahin, A.; Pasyar, A. The Use of Dexamethasone in the Treatment of COVID-19. Ann. Med. Surg. 2020, 56, 218–219.
[CrossRef]
24. Cain, D.W.; Cidlowski, J.A. Immune Regulation by Glucocorticoids. Nat. Rev. Immunol. 2017, 17, 233–247. [CrossRef] [PubMed]
25. Villoutreix, B.O.; Beaune, P.H.; Tamouza, R.; Krishnamoorthy, R.; Leboyer, M. Prevention of COVID-19 by Drug Repurposing:
Rationale from Drugs Prescribed for Mental Disorders. Drug Discov. Today 2020, 25, 1287–1290. [CrossRef] [PubMed]
26. Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-Approved Drug Ivermectin Inhibits the Replication of
SARS-CoV-2 In Vitro. Antiviral Res. 2020, 178, 104787. [CrossRef] [PubMed]
27. Tay, M.Y.F.; Fraser, J.E.; Chan, W.K.K.; Moreland, N.J.; Rathore, A.P.; Wang, C.; Vasudevan, S.G.; Jans, D.A. Nuclear Localization
of Dengue Virus (DENV) 1–4 Non-Structural Protein 5; Protection against All 4 DENV Serotypes by the Inhibitor Ivermectin.
Antiviral Res. 2013, 99, 301–306. [CrossRef] [PubMed]
28. Chand, M.; Hopkins, S.; Dabrera, G.; Achison, C.; Barclay, W.; Ferguson, N.; Volz, E.; Loman, N.; Rambaut, A.; Barrett, J.
Investigation of Novel SARS-COV-2 Variant Variant of Concern 202012/01; Public Health England: London, UK, 2020; pp. 1–11.
29. Leung, K.; Shum, M.H.; Leung, G.M.; Lam, T.T.; Wu, J.T.; Ty, T. Early Transmissibility Assessment of the N501Y Mutant Strains of
SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance 2021, 26, 2002106. [CrossRef] [PubMed]
30. Tegally, H.; Wilkinson, E.; Giovanetti, M.; Iranzadeh, A.; Fonseca, V.; Giandhari, J.; Doolabh, D.; Pillay, S.; San, E.J.; Msomi, N.; et al.
Emergence and Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with
Multiple Spike Mutations in South Africa. medRxiv 2020, 1–19, in preprint.
31. Wise, J. Covid-19: New Coronavirus Variant Is Identified in UK. BMJ 2020, 371, m4857. [CrossRef]
32. Wang, J.; Tao, W.; Chen, X.; Farokhzad, O.C.; Liu, G. Emerging Advances in Nanotheranostics with Intelligent Bioresponsive
Systems. Theranostics 2017, 7, 3915–3919. [CrossRef]
33. Mosselhy, D.A.; Assad, M.; Sironen, T.; Elbahri, M. Nanotheranostics: A Possible Solution for Drug-Resistant Staphylococcus aureus
and Their Biofilms? Nanomaterials 2021, 11, 82. [CrossRef]
34. Machhi, J.; Shahjin, F.; Das, S.; Paetl, M.; Abdelmoaty, M.M.; Cohen, J.D.; Singh, P.A.; Baldi, A.; Bajwa, N.; Kumar, R.; et al.
Nanocarrier Vaccines for SARS-CoV-2. Adv. Drug Deliv. Rev. 2021. [CrossRef]
35. Shin, M.D.; Shukla, S.; Chung, Y.H.; Beiss, V.; Chan, S.K.; Ortega-Rivera, O.A.; Wirth, D.M.; Chen, A.; Sack, M.; Pokorski, J.K.; et al.
COVID-19 Vaccine Development and a Potential Nanomaterial Path Forward. Nat. Nanotechnol. 2020, 15, 646–655. [CrossRef]
[PubMed]
36. Nanomedicine and the COVID-19 Vaccines. Nat. Nanotechnol. 2020, 15, 963. [CrossRef]
37. Teengam, P.; Siangproh, W.; Tuantranont, A.; Vilaivan, T.; Chailapakul, O.; Henry, C.S. Multiplex Paper-Based Colorimetric
DNA Sensor Using Pyrrolidinyl Peptide Nucleic Acid-Induced AgNPs Aggregation for Detecting MERS-CoV, MTB, and HPV
Oligonucleotides. Anal. Chem. 2017, 89, 5428–5435. [CrossRef] [PubMed]
38. Moitra, P.; Alafeef, M.; Dighe, K.; Frieman, M.B.; Pan, D. Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene
Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles. ACS Nano 2020, 14, 7617–7627. [CrossRef] [PubMed]
39. Łoczechin, A.; Séron, K.; Barras, A.; Giovanelli, E.; Belouzard, S.; Chen, Y.T.; Metzler-Nolte, N.; Boukherroub, R.; Dubuisson, J.;
Szunerits, S. Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. ACS Appl. Mater. Interfaces
2019, 11, 42964–42974. [CrossRef] [PubMed]
40. Ting, D.; Dong, N.; Fang, L.; Lu, J.; Bi, J.; Xiao, S.; Han, H. Multisite Inhibitors for Enteric Coronavirus: Antiviral Cationic Carbon
Dots Based on Curcumin. ACS Appl. Nano Mater. 2018, 1, 5451–5459. [CrossRef]
Nanomaterials 2021, 11, 796 22 of 24
41. Du, T.; Liang, J.; Dong, N.; Lu, J.; Fu, Y.; Fang, L.; Xiao, S.; Han, H. Glutathione-Capped Ag2S Nanoclusters Inhibit Coronavirus
Proliferation through Blockage of Viral RNA Synthesis and Budding. ACS Appl. Mater. Interfaces 2018, 10, 4369–4378. [CrossRef]
[PubMed]
42. Fischer, H.C.; Chan, W.C. Nanotoxicity: The Growing Need for In Vivo Study. Curr. Opin. Biotechnol. 2007, 18, 565–571. [CrossRef]
43. Maynard, A.D.; Aitken, R.J.; Butz, T.; Colvin, V.; Donaldson, K.; Oberdörster, G.; Philbert, M.A.; Ryan, J.; Seaton, A.; Stone, V.; et al.
Safe Handling of Nanotechnology. Nature 2006, 444, 267–269. [CrossRef]
44. Wu, Z.; Shi, P.; Lim, H.K.; Ma, Y.; Setyawati, M.I.; Bitounis, D.; Demokritou, P.; Ng, K.W.; Tay, C.Y. Inflammation Increases
Susceptibility of Human Small Airway Epithelial Cells to Pneumonic Nanotoxicity. Small 2020, 16, 1–7. [CrossRef] [PubMed]
45. Bai, C.; Tang, M. Toxicological Study of Metal and Metal Oxide Nanoparticles in Zebrafish. J. Appl. Toxicol. 2020, 40, 37–63.
[CrossRef] [PubMed]
46. Chen, C.; Leong, D.T.; Lynch, I. Rethinking Nanosafety: Harnessing Progress and Driving Innovation. Small 2020, 16, 2–5.
47. Hadrup, N.; Zhernovkov, V.; Jacobsen, N.R.; Voss, C.; Strunz, M.; Ansari, M.; Schiller, H.B.; Halappanavar, S.; Poulsen, S.S.;
Kholodenko, B.; et al. Acute Phase Response as a Biological Mechanism-of-Action of (Nano)Particle-Induced Cardiovascular
Disease. Small 2020, 16, 1907476. [CrossRef]
48. Tsoi, K.M.; Dai, Q.; Alman, B.A.; Chan, W.C.W. Are Quantum Dots Toxic? Exploring the Discrepancy between Cell Culture and
Animal Studies. Acc. Chem. Res. 2013, 46, 662–671. [CrossRef] [PubMed]
49. Mosselhy, D.A.; Assad, M.; Sironen, T.; Elbahri, M. Could Nanotheranostics Be the Answer to the Coronavirus Crisis? Glob.
Challenges 2021. [CrossRef]
50. Asuri, P.; Bale, S.S.; Karajanagi, S.S.; Kane, R.S. The Protein-Nanomaterial Interface. Curr. Opin. Biotechnol. 2006, 17, 562–568.
[CrossRef]
51. Nel, A.E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E.M.V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Under-
standing Biophysicochemical Interactions at the Nano-Bio Interface. Nat. Mater. 2009, 8, 543–557. [CrossRef]
52. Caracciolo, G.; Farokhzad, O.C.; Mahmoudi, M. Biological Identity of Nanoparticles in Vivo: Clinical Implications of the Protein
Corona. Trends Biotechnol. 2017, 35, 257–264. [CrossRef]
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